despit
extraordinari
advanc
diagnost
therapeut
vaccin
develop
emerg
reemerg
viral
diseas
occur
past
sever
decad
sever
factor
contribut
emerg
recent
epidem
identifi
includ
relat
microbi
agent
human
host
human
environ
also
among
import
factor
genet
adapt
microbi
agent
intern
travel
human
suscept
infect
popul
growth
age
popul
climat
weather
chang
expand
vector
habitat
three
recent
exampl
diseas
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
chikungunya
zika
virus
repres
new
viral
entiti
virus
emerg
new
geograph
local
character
novel
complic
howev
import
newest
exampl
emerg
infecti
diseas
human
immunodefici
viru
hiv
infect
emerg
centuri
ago
primat
host
subsequ
spread
within
human
popul
hivrel
acquir
immun
defici
syndrom
aid
dread
complic
first
recogn
men
sex
men
inject
drug
user
recipi
blood
transfus
subsequ
year
francoi
luc
montagni
other
institut
pasteur
pari
identifi
etiolog
agent
diseas
call
human
immunodefici
viru
hiv
french
virologist
award
nobel
prize
discoveri
present
howev
hiv
infect
becom
global
diseas
affect
heterosexu
individu
especi
within
develop
world
viru
hiv
belong
retrovirida
famili
genu
lentiviru
two
serotyp
hiv
hiv
etiolog
agent
epidem
aid
see
differ
serotyp
tabl
hiv
lipid
envelop
two
glycoprotein
gp
insert
two
viral
glycoprotein
respons
attach
host
cell
beneath
envelop
matrix
core
protein
nucleocapsid
protein
within
viral
core
lie
two
copi
viral
ribonucl
acid
rna
genom
togeth
proteas
integras
revers
transcriptas
enzym
fig
structur
codifi
differ
viral
gene
human
immunodefici
viru
enter
bodi
human
bind
specif
receptor
hiv
viru
attach
receptor
present
surfac
cell
either
coreceptor
replic
infect
cell
bind
receptor
viru
use
machineri
cell
replic
spread
throughout
bodi
process
replic
carri
sever
stage
bind
fusion
revers
transcript
integr
replic
assembl
bud
pathogenesi
hiv
infect
complex
multifactori
incomplet
understood
hiv
infect
main
target
rest
memori
cell
select
deplet
cell
accompani
aberr
activ
compon
immun
system
immun
activ
major
forc
drive
hiv
process
associ
viremia
neg
correl
cell
count
chronic
infect
cellular
solubl
factor
play
import
role
acut
chronic
immun
activ
progress
aid
tabl
fig
epo
erythropoietin
tpo
thyroid
peroxidas
tshr
thyroid
stimul
hormon
receptor
ps
phosphatidylserin
pi
phosphatidylinositol
pc
phosphatidylcholin
beta
gbm
glomerular
basal
membran
presenc
autoantibodi
associ
lower
cell
count
increas
mortal
impli
prognost
signific
phenomenon
context
hiv
infect
hiv
immun
dysregul
involv
b
cell
may
lead
autoimmun
phenomena
uniqu
hiv
diseas
classic
autoimmun
clinic
syndrom
sever
possibl
mechan
autoimmun
manifest
hiv
infect
describ
molecular
mimicri
appear
one
relev
hiv
viru
molecular
similar
selfantigen
may
therefor
induc
antibodi
crossreact
lead
develop
autoimmun
diseas
whether
autoimmun
compon
natur
immun
hiv
clinic
signific
role
neutral
antibodi
remain
defin
direct
effect
hiv
endotheli
synovi
hematopoiet
cellsincreas
cytotox
cell
activityincreas
express
autoantigensmolecular
mimicri
close
year
elaps
sinc
onset
hivaid
pandem
total
million
individu
live
infect
includ
million
newli
infect
individu
million
death
includ
adult
children
age
year
million
live
hiv
antiretrovir
therapi
extraordinari
progress
understand
pathogenesi
natur
cours
diagnost
combin
antiretrovir
therapi
cart
occur
led
signific
improv
morbid
mortal
date
statu
consider
proport
hivaid
patient
chang
nearfat
disord
secondari
opportunist
infect
chronic
diseas
cardiovascular
renal
diabet
malign
autoimmun
comorbid
disord
becom
preval
relev
latter
make
topic
great
relev
import
clinician
includ
rheumatologist
practition
deal
condit
longitudin
descript
compar
studi
allow
certainti
defin
impact
hiv
infect
precart
postcart
era
howev
review
discuss
avail
data
hiv
infect
rheumat
manifest
winchest
et
al
first
report
associ
hiv
rheumat
diseas
describ
seri
patient
aid
reiter
diseas
sinc
time
sever
report
publish
preval
rheumat
manifest
among
hiv
infect
patient
rang
common
complaint
usual
intermitt
polyarticular
report
preval
also
frequent
report
difficult
separ
myopathi
estim
preval
rate
may
mislead
result
casecontrol
studi
reveal
myalgia
common
hiv
infect
uninfect
control
frequenc
precart
increas
postcart
howev
studi
show
opposit
therefor
clear
whether
therapi
improv
exacerb
myalgia
syndrom
character
acut
onset
sever
intens
arthralgia
present
typic
one
usual
larg
joint
hivposit
patient
short
durat
hour
associ
synov
estim
preval
among
us
patient
late
stage
infect
similar
rate
observ
among
patient
argentina
syndrom
report
case
seri
africa
asia
contin
effect
cart
syndrom
current
welldefin
syndrom
character
acut
onset
arthriti
larg
joint
noneros
last
less
week
absenc
hla
posit
radiolog
chang
distinct
known
rheumat
diseas
known
infect
trigger
classic
featur
preval
rate
rang
studi
perform
usa
report
demonstr
case
occur
men
commonli
cdc
stage
iv
hiv
infect
cohort
studi
africa
report
preval
african
studi
report
high
preval
rate
case
rea
associ
late
stage
immunosuppress
seen
hivinfect
patient
estim
preval
rea
precart
low
high
variabl
depend
sampl
studi
usa
two
cohort
studi
perform
questionnair
san
francisco
men
health
studi
john
hopkin
multicent
aid
cohort
studi
find
increas
rea
howev
patient
studi
earli
phase
hivinfect
latin
american
countri
mexico
argentina
frequenc
rea
found
increas
spain
low
mode
transmiss
appear
explain
differ
sexuallytransmit
mexico
argentina
intraven
drug
use
spain
low
frequenc
rea
report
cohort
mode
transmiss
iv
drug
use
great
interest
situat
africa
prior
hiv
pandem
rea
rare
seen
might
explain
basi
rariti
follow
advent
hiv
howev
rea
becam
common
occurr
among
hiv
infect
individu
major
neg
epidemiolog
studi
zambia
reveal
presenc
allel
confer
protect
effect
rapid
progress
hiv
studi
asian
countri
point
rea
hiv
patient
rare
occur
regard
mode
transmiss
hiv
appear
similar
asia
africa
heterosexu
high
preval
arthritogen
pathogen
might
suggest
factor
includ
genet
might
play
role
conclud
rea
rel
common
western
world
precart
preval
greatli
diminish
postcart
similar
situat
rea
occur
psa
sever
studi
precart
era
reveal
increas
afflict
hiv
infect
patient
rate
preval
psa
hiv
patient
precart
higher
gener
popul
vs
respect
rate
incid
similar
popul
annum
vs
popul
studi
howev
differ
stage
hiv
infect
also
note
patient
hiv
psoriasi
sever
persist
lesion
compar
patient
classic
psoriasi
hiv
sever
morpholog
type
coexist
patient
psa
sever
deform
eros
refractori
convent
therapi
incid
preval
psoriasi
psa
africa
low
even
though
black
african
one
risk
allel
psoriasi
howev
drastic
chang
follow
advent
hiv
disord
increasingli
recogn
african
popul
asian
popul
low
preval
rate
psoriasi
psa
also
chang
follow
hiv
pandem
postcart
disord
greatli
diminish
africa
asia
prototyp
spondyloarthritid
common
western
world
much
less
common
among
subsaharan
african
frequenc
low
frequenc
howev
west
africa
higher
despit
higher
preval
rare
seen
region
howev
chang
follow
onset
hiv
sever
report
describ
associ
report
african
popul
gener
report
hiv
infect
patient
report
data
might
suggest
uncommon
hiv
probabl
patient
hiv
aid
classifi
undifferenti
spondyloarthr
absenc
radiograph
test
pauciti
longterm
followup
studi
immun
dysregul
inher
hiv
infect
clinic
manifest
may
mimic
interfer
diagnosi
rheumatoid
arthriti
hiv
patient
may
exhibit
symmetr
polyarthr
tend
seroneg
part
howev
eros
form
seroposit
rheumatoid
factor
rf
also
describ
hand
presenc
low
titer
rf
ccp
antibodi
patient
hiv
may
lead
erron
diagnosi
ra
hiv
patient
may
also
exhibit
high
proport
rf
ccp
antibodi
decreas
initi
cart
suggest
hiv
capabl
induc
autoantibodi
followup
studi
howev
hiv
popul
reveal
develop
ra
addit
well
recogn
presenc
falseposit
hiv
serolog
patient
ra
suggest
crossreact
hiv
diagnost
test
patient
ra
anoth
import
issu
impact
de
novo
hiv
infect
establish
ra
earli
observ
pandem
ra
patient
might
go
remiss
develop
aid
howev
presenc
activ
ra
diseas
includ
radiolog
progress
seen
despit
profound
state
immunosuppress
also
develop
de
novo
rf
ccp
antibodi
posit
ra
seen
well
control
hiv
infect
normal
cell
count
neg
hiv
viral
load
ra
diseas
activ
behav
ident
fashion
ra
seen
hiv
neg
individu
therapi
hiv
patient
affect
withra
well
connect
tissu
disord
well
defin
safe
treat
ident
manner
nonhiv
afflict
popul
caution
howev
prophylaxi
opportunist
infect
exert
immunosuppress
biolog
therapi
use
sle
rare
report
associ
hiv
infect
repres
diagnost
therapeut
challeng
especi
coexist
patient
hiv
impact
sle
diagnosi
assess
diseas
activ
hiv
infect
sle
share
sever
clinic
featur
laboratori
find
make
diagnosi
extrem
difficult
varieti
constitut
manifest
fever
arthralgia
arthriti
myalgia
skin
rash
lymph
node
enlarg
cytopenia
pulmonari
cardiovascular
renal
cn
involv
observ
activ
sle
hiv
infect
varieti
autoantibodi
includ
ana
antidsdna
antism
anticardiolipin
antibodi
seen
disord
hypocomplementemia
secondari
hiv
describ
find
may
use
distinguish
lupu
activ
hiv
infect
diagnost
test
hiv
report
falseposit
result
sle
patient
multipl
studi
report
autoantibodi
reactiv
hiv
antigen
find
make
necessari
need
perform
confirmatori
test
viral
rna
pcr
hivwestern
blot
assay
hiv
infect
describ
ra
may
import
effect
natur
cours
sle
decreas
lymphocyt
might
amelior
sle
diseas
activ
induc
remiss
howev
sle
diseas
activ
may
persist
hiv
infect
relat
use
cart
lupu
may
also
impact
hiv
infect
homolog
selfantigen
lupu
patient
viral
protein
identifi
antibodi
product
includ
neutral
antibodi
might
develop
sle
may
confer
protect
hiv
infect
molecular
mimicri
mechan
addit
antimalari
drug
chloroquin
deriv
use
sle
therapi
may
antihiv
activ
potenti
role
observ
low
incid
hiv
infect
patient
sle
describ
treatment
sle
glucocorticoid
immunosuppress
drug
challeng
may
trigger
viral
replic
rapid
progress
diseas
hand
use
cyclophosphamid
lupu
flare
may
also
result
increas
viral
load
viral
load
becom
undetect
cyclophosphamid
discontinu
therefor
treatment
activ
lupu
individu
aim
reach
balanc
hiv
infect
lupu
activ
associ
hivrel
discoid
lupu
hiv
rare
report
case
describ
occur
onset
cart
associ
undetect
hiv
viral
load
normal
tcell
count
presenc
antiphospholipid
antibodi
includ
anticardiolipin
lupu
anticoagul
antibodi
seen
hiv
patient
howev
develop
clinic
manifest
characterist
ap
uncommon
hand
case
report
literatur
antiphospholipid
antibodi
glycoprotein
appear
lower
frequenc
associ
hiv
infect
ssc
rare
report
case
two
male
patient
develop
local
scleroderma
sever
year
cart
two
patient
develop
symptom
diffus
system
sclerosi
one
two
case
background
immunosuppress
respond
well
therapi
steroid
cart
patient
develop
symptom
ssc
year
hiv
infect
cart
good
virolog
suppress
normal
cell
count
diseas
rare
report
preval
polymyos
report
dermatomyos
occur
less
frequent
present
occur
stage
hiv
infect
hivassoci
polymyos
usual
mild
diseas
activ
often
difficult
recogn
especi
popul
frequent
manifest
gener
weak
debilit
cours
polymyos
dermatomyos
carri
rel
good
prognosi
respond
well
glucocorticoid
immunosuppress
therapi
requir
criteria
hiv
infect
posit
serolog
bilater
salivari
gland
enlarg
xerostomiapersist
signssymptom
month
morehistolog
confirm
salivari
lacrim
gland
lymphocyt
infiltr
without
granulomatosi
neoplast
involv
hivrel
dil
character
salivari
lacrim
glandular
swell
sicca
symptom
vari
intens
preval
complic
highest
among
african
american
infect
individu
associ
hla
class
ii
allel
seen
racial
group
dil
occur
patient
whose
diseas
less
advanc
stage
syndrom
usual
present
ill
gener
associ
sicca
sign
bilater
parotid
gland
swell
lymphadenopathi
extraglandular
organ
involv
dil
also
character
cell
infiltr
lack
autoantibodi
antiro
antila
although
may
present
except
extraglandular
viscer
infiltr
lung
common
extraglandular
organ
involv
affect
present
lymphocyt
interstiti
pneumon
lip
natur
histori
also
chang
sinc
introduct
cart
less
frequent
seen
includ
extraglandular
manifest
lip
chen
et
al
conduct
nationwid
populationbas
studi
taiwanes
popul
show
incid
rate
dil
personyear
higher
compar
gener
popul
incid
higher
patient
without
cart
patient
cart
support
notion
hiv
interven
pathogenesi
dil
cart
reduc
risk
acquir
dil
clinic
laboratori
featur
dil
shown
tabl
dil
patient
mild
symptom
may
requir
specif
treatment
glucocorticoid
immunosuppress
drug
consid
patient
progress
glandular
involv
entir
clinic
spectrum
size
involv
blood
vessel
seen
hivassoci
vasculitid
incid
vascul
hiv
infect
rel
low
presenc
howev
vari
accord
ethnic
origin
appear
higher
preval
orient
vascul
report
patient
infect
hiv
commonli
profound
stage
immunosuppress
associ
hepat
b
infect
also
report
earli
hiv
stage
describ
rheumat
manifest
factor
ethnic
origin
rout
transmiss
might
implic
preval
zhang
et
al
report
high
preval
vascul
compar
rheumat
syndrom
report
case
vascul
cohort
chines
patient
main
rout
transmiss
popul
blood
transfus
varieti
syndrom
report
includ
diseas
henochschonlein
purpura
digit
gangren
central
nervou
system
vascul
polyarter
nodosa
pan
preval
form
vascul
coexist
hiv
infect
relat
hepat
b
infect
like
classic
form
occur
stage
hiv
diseas
clinic
cours
hivrel
pan
exhibit
major
differ
comparison
classic
hbvrelat
clinic
less
aggress
peripher
neuropathi
common
clinic
manifest
tabl
presenc
antineutrophil
cytoplasm
antibodi
especi
panca
high
clinic
signific
well
defin
cart
play
benefici
role
treatment
due
direct
role
hiv
pathogenesi
pan
hand
impact
virus
includ
hepat
b
hepat
c
cytomegaloviru
cmv
epsteinbarr
ebv
varicellazost
viru
vzv
often
coexist
hiv
posit
individu
fulli
character
glucocorticoid
success
use
mani
case
hivassoci
vascul
immunosuppress
drug
reserv
resist
patient
form
vascul
henochschonlein
purpura
might
occur
secondari
variou
infecti
trigger
ancaassoci
vascul
extrem
rare
hiv
infect
patient
cryoglobulinemia
may
coexist
hiv
infect
presenc
usual
asymptomat
respond
well
cart
regimen
cart
era
hivinfect
patient
shown
decreas
level
serum
cryoglobulin
osteoarticular
infect
due
pyogen
bacteri
occur
frequent
patient
hiv
infect
compar
gener
popul
incid
musculoskelet
infect
patient
hiv
appear
low
case
seri
report
usa
europ
itali
africa
shown
septic
arthriti
occur
less
frequent
hiv
patient
retrospect
hiv
cohort
studi
show
rel
low
risk
septic
arthriti
marquez
et
al
studi
prospect
patient
hiv
infect
refer
rheumatolog
clinic
new
orlean
report
preval
septic
arthriti
osteomyel
respect
atyp
mycobacteri
mycobacterium
haemophilum
kansasii
fungal
candida
sporotrichosi
schenckii
infect
rare
occur
except
advanc
hiv
infect
count
less
introduct
cart
manag
patient
infect
hiv
mark
mileston
histori
medicin
led
signific
chang
natur
histori
longterm
outcom
occurr
comorbid
importantli
drastic
reduct
mortal
signific
declin
inflammatori
rheumat
complic
observ
follow
introduct
cart
great
interest
import
new
group
rheumat
disord
emerg
cover
spectrum
system
autoimmun
autoinflammatori
diseas
pose
new
clinic
challeng
tabl
current
three
diseas
deserv
special
attent
avascular
necrosi
osteoporosi
immun
reconstitut
inflammatori
syndrom
prior
introduct
cart
reactiv
arthriti
psoriat
arthriti
pain
articular
syndrom
common
rheumat
disord
observ
hivinfect
patient
howev
introduct
cart
incid
diseas
decreas
dramat
new
form
rheumat
diseas
appear
calabres
et
al
conduct
longitudin
cohort
studi
demonstr
postcart
declin
rea
psa
myositi
marquez
et
al
report
rise
septic
disord
malign
declin
spondyloarthr
dil
also
affect
cart
basu
et
al
report
declin
incid
dil
mastroianni
et
al
report
opposit
result
previous
mention
chen
et
al
report
cart
reduc
risk
acquir
dil
contrast
parperi
et
al
observ
higher
risk
rheumat
diseas
except
avascular
necrosi
avn
psoriasi
similar
find
report
yang
et
al
show
preval
autoimmun
arthriti
among
hiv
infect
patient
similar
gener
popul
recent
studi
perform
uk
assess
hivposit
patient
musculoskelet
symptom
januari
decemb
major
patient
refer
evid
inflammatori
rheumat
diseas
instead
diagnos
region
musculoskelet
pain
specif
soft
tissu
disord
chronic
widespread
pain
osteoarthr
among
remain
inflammatori
diagnos
made
often
would
expect
gener
popul
except
spondyloarthr
studi
deal
incid
preval
chronolog
rheumat
disord
associ
hiv
infect
aid
two
larg
studi
one
taiwan
second
franc
merit
discuss
first
studi
yen
et
al
report
incid
aid
nationwid
hivaid
patient
plwha
cohort
taiwan
compar
gener
popul
standard
incid
rate
sir
higher
incid
syndrom
psoriasi
sle
autoimmun
hemolyt
anemia
aha
uveiti
interest
observ
lower
risk
develop
despit
high
preval
taiwanes
peopl
contrast
plwha
receiv
cart
higher
sir
psoriasi
aha
uveiti
receiv
cart
higher
sir
syndrom
psoriasi
ra
sle
autoimmun
disord
lebrun
et
al
also
conduct
epidemiolog
studi
french
nationwid
hiv
cohort
estim
preval
inflammatori
autoimmun
diseas
iad
among
patient
live
hiv
plhiv
cart
era
januari
juli
describ
occurr
accord
cart
onset
immunevirolog
statu
hepat
c
viru
hcv
andor
hepat
b
viru
coinfect
result
show
sever
iad
includ
psoriasi
sarcoidosi
ra
grave
diseas
aha
immun
thrombocytopenia
chronic
inflammatori
bowel
diseas
preval
diseas
major
patient
develop
iad
hiv
infect
mean
delay
year
addit
patient
develop
iad
diagnosi
hiv
infect
cart
undetect
hiv
viral
load
compar
data
taiwan
french
studi
geograph
variabl
term
iad
observ
studi
confirm
previou
report
literatur
concern
relationship
hivaid
rheumat
disord
resurg
autoimmun
disord
may
occur
follow
introduct
cart
due
restor
immun
compet
phenomenon
known
iri
link
rapidli
recov
immun
system
appear
directli
relat
increas
cell
cell
cell
ratio
increas
cytokin
level
fig
iri
may
develop
follow
manner
paradox
iri
subset
affect
individu
develop
symptom
sign
associ
known
opportunist
infect
oi
treatment
underway
exacerb
despit
earlier
clinic
respons
therapi
prior
artb
unmask
iri
patient
subset
experi
new
oi
mark
inflammatori
compon
follow
initi
art
recent
report
howev
defin
allnew
oi
first
month
art
case
unmask
iri
sever
classif
criteria
iri
propos
none
valid
report
incid
iri
vari
wide
depend
offend
microorgan
involv
iri
associ
new
infect
exacerb
quiescent
infect
also
may
occur
either
new
appear
exacerb
previous
quiescent
occult
autoimmun
syndrom
calabres
et
al
conduct
prospect
longitudin
cohort
studi
describ
case
associ
iri
includ
sarcoidosi
ra
sle
iri
symptomatolog
may
ensu
day
month
art
begin
case
resolv
spontan
time
becom
lifethreaten
sever
necessit
therapeut
intervent
howev
usual
necessari
discontinu
cart
time
iri
gener
selflimit
requir
lifelong
therapi
life
span
hivinfect
individu
increas
new
comorbid
condit
develop
includ
osteopenia
osteoporosi
increas
risk
bone
fractur
estim
hiv
infect
individu
osteopenia
also
time
risk
develop
osteoporosi
nonhiv
infect
individu
estim
preval
osteoporosi
hiv
popul
osteopenia
decreas
bone
densiti
first
year
cart
rate
fractur
hiv
popul
compar
control
nonhiv
popul
addit
classic
osteoporosi
risk
factor
hivspecif
risk
factor
defin
aid
histori
low
cell
count
coinfect
hepat
c
antiretrovir
therapi
may
contribut
increas
risk
osteoporosi
specif
guid
manag
hiv
patient
decreas
bone
densiti
hiv
patient
includ
list
patient
risk
osteoporosi
manag
guidelin
howev
two
instrument
bmd
applic
frax
use
assess
hiv
patient
problem
especi
treatment
consid
presenc
osteopenia
kept
mind
howev
frax
valid
hivposit
popul
regard
therapi
addit
adequ
nutrit
includ
calcium
vitamin
modif
lifestyl
pharmacolog
therapi
bisphosphon
alendron
zoledron
acid
shown
posit
effect
bmd
toler
similar
found
gener
popul
therapi
evalu
osteonecrosi
avn
anoth
complic
associ
hiv
infect
affect
hip
major
joint
might
lead
sever
disabl
incid
estim
time
compar
gener
popul
preval
also
increas
almost
similar
preval
report
patient
high
risk
osteonecrosi
context
varieti
underli
diseas
etiolog
complic
poorli
understood
littl
known
potenti
risk
factor
hiv
patient
use
glucocorticoid
hyperlipidemia
contribut
osteonecrosi
seen
hiv
patient
studi
need
fulli
character
potenti
risk
factor
complic
introduct
cart
profound
effect
morbid
surviv
hivinfect
patient
convers
also
correct
hiv
infect
also
impact
great
deal
natur
histori
therapeut
intervent
autoimmun
diseas
due
presenc
underli
immunosuppress
state
complic
occur
immunosuppress
drug
biolog
agent
administ
may
lead
seriou
complic
includ
infect
treatment
autoimmun
diseas
aid
similar
hivposit
hivneg
patient
signific
proport
hivassoci
aid
includ
inflammatori
musculoskelet
involv
respond
well
convent
therapi
nsaid
narcot
drug
dmard
refractori
case
may
need
use
biolog
agent
especi
tnf
inhibitor
use
agent
may
repres
challeng
especi
patient
coexist
hepat
infect
publish
report
indic
presenc
stabl
cell
count
low
viral
load
use
safe
efficaci
consid
immun
suppress
therapi
import
keep
mind
cell
necessari
control
intracellular
extracellular
bacteria
parasit
virus
presenc
tnf
need
use
control
infect
increas
favor
replic
viral
particl
rate
seriou
infect
hivinfect
patient
treat
inhibitor
concomit
aid
compar
observ
ra
patient
receiv
inhibitor
present
biolog
agent
dmard
includ
methotrex
leflunomid
mycophenol
mofetil
azathioprin
cyclophosphamid
cyclosporin
recommend
patient
cell
count
hiv
viral
activ
complet
suppress
glucocorticoid
hydroxychloroquin
sulfasalazin
shown
safe
welltoler
current
howev
studi
good
qualiti
use
biolog
therapi
treat
inflammatori
disord
hivinfect
individu
therefor
conclud
efficaci
safeti
biolog
therapi
hivinfect
popul
hiv
patient
immunosuppress
therapi
increas
risk
infect
reactiv
close
attent
associ
tuberculosi
varicella
zoster
opportunist
infect
pneumocysti
jirovecii
pj
kept
mind
patient
screen
hiv
viral
load
hbv
hcv
tb
infect
accord
endem
geographi
guidelin
regard
use
synthet
diseasemodifi
antirheumat
drug
sdmard
biolog
patient
histori
hepat
b
hepat
c
infect
regard
pj
consensu
guidelin
prophylaxi
pcp
connect
tissu
diseas
prophylaxi
tb
recommend
follow
cdc
guidelin
recommend
screen
latent
tb
prior
initi
chronic
therapi
glucocorticoid
chemoprophylaxi
either
isoniazid
inh
month
rifampicin
combin
inh
month
initi
presenc
latent
tb
infect
ltbi
autoimmun
inflammatori
rheumat
disord
occur
patient
hiv
infect
presenc
poor
good
immunevirolog
control
cart
aid
preval
accord
cart
cohort
studi
gener
aid
appear
follow
diagnosi
hiv
infect
also
cart
clinic
manifest
observ
hiv
popul
similar
seen
gener
popul
glucocorticoid
immunosuppress
agent
seem
effect
welltoler
prophylaxi
infect
import
comorbid
osteoporosi
avn
appear
consequ
age
hivinfect
popul
appropri
prevent
measur
taken
pathophysiolog
hivrel
autoimmun
rheumat
diseas
well
understood
intric
enigma
associ
merit
investig
